Retinopathy of Prematurity News and Research

RSS

Discovery offers promising alternative to current therapies for AMD and ROP

A research team led by scientists at Beth Israel Deaconess Medical Center and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal diseases.

3 Nov 2015

Shire acquires Foresight Biotherapeutics for $300 million

Shire plc announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million.

3 Aug 2015

JAMA: Extremely preterm infants enrolled in randomized clinical trials experience neither better nor worse outcomes

In a group of more than 5,000 extremely preterm infants, important in-hospital outcomes were neither better nor worse in infants enrolled in randomized clinical trials (RCTs) compared with eligible but nonenrolled infants, findings that may provide reassurance regarding concerns about performing RCTs in this vulnerable population, according to a study in the June 16 issue of JAMA.

17 Jun 2015

Preterm babies treated with bevacizumab for severe retinopathy of prematurity have lower motor scores

Preterm babies with retinopathy of prematurity (ROP) treated using bevacizumab, a growth inhibitor, have been found to have lower motor scores than babies treated with traditional laser ablation. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Denver, Colo.

7 May 2015

Blocking Slit2 protein prevents blood vessel development that causes vasoproliferative ocular diseases

Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific factor, VEGF. A team of Inserm researchers at the Vision Institute (Inserm/CNRS/Pierre and Marie Curie University), in association with a team from the Yale Cardiovascular Research Center, have demonstrated in an animal model that blocking another protein, Slit2, prevents the pathological blood vessel development that causes these diseases.

22 Apr 2015

Reversing effects of early stage age-related macular degeneration may be possible

A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.

3 Feb 2015

Two UTHealth professors selected as AAAS Fellows for their efforts to prevent blindness

Two professors in the School of Public Health at The University of Texas Health Science Center at Houston - Stephen Daiger, Ph.D., and Robert Hardy, Ph.D. - have been elected to the rank of Fellow in the American Association for the Advancement of Science for their efforts to prevent blindness.

14 Jan 2015

Endothelin gene expression linked to vision loss in premature babies

A gene known to play a major role in constricting blood vessels also appears to be a major player in the aberrant blood vessel growth that can destroy the vision of premature babies.

11 Nov 2014

Study validates telemedicine approach to ROP screening

Trained non-physician evaluators who studied retinal images transmitted to computer screens at a remote central reading center successfully identified newborn infants likely to require a specialized medical evaluation for retinopathy of prematurity (ROP), a leading cause of treatable blindness.

28 Jun 2014

Telemedicine is effective strategy to screen for potentially blinding disease in infants

Telemedicine is an effective strategy to screen for the potentially blinding disease known as retinopathy of prematurity (ROP), according to a study funded by the National Eye Institute (NEI).

27 Jun 2014

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.

19 May 2014

Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops

Eyedrops administered to infants as part of routine outpatient retinopathy of prematurity (ROP) screening can have life-threatening consequences. A case report published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) describes cardiopulmonary arrest in a 27-week-old infant following administration of three sets of cyclopentolate 0.2%/phenylephrine 1% (Cyclomydril) eyedrops.

3 Apr 2014

Research may lead the way toward new treatments for proliferative retinopathies

A new report published online in The FASEB Journal may lead the way toward new treatments or a cure for a common cause of blindness (proliferative retinopathies). Specifically, scientists have discovered that the body's innate immune system does more than help ward off external pathogens.

27 Mar 2014

Researchers evaluate feasibility of using stem cell therapies on preterm infants to treat BPD

Advances in neonatal care for very preterm infants have greatly increased the chances of survival for these fragile infants. However, preterm infants have an increased risk of developing bronchopulmonary dysplasia (BPD), a serious lung disease, which is a major cause of death and lifelong complications.

6 Feb 2014

Study investigates association between preterm birth and later retinal detachment

Children born extremely prematurely have up to a 19 times greater risk of retinal detachment later in life than peers born at term, according to a Swedish study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology.

8 Nov 2013

Viewpoints: 'Reasonable' debate about health law's 'rate shock; 'absurdity' of Sebelius' account of fund raising; Obama killed the grand bargain

Many of us have been wondering whether it's possible to have an honest, reasonable debate about Obamacare. To my pleasant surprise, one may finally be starting.

7 Jun 2013

Oxygenation targets and outcomes in premature infants

In a randomized trial performed to help resolve the uncertainty about the optimal oxygen saturation therapy in extremely preterm infants, researchers found that targeting saturations of 85 percent to 89 percent compared with 91 percent to 95 percent had no significant effect on the rate of death or disability at 18 months, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the Pediatric Academic Societies annual meeting.

6 May 2013